TouchRESPIRATORY were delighted to catch up with Dr Aaron Waxman (Brigham and Women’s Hospital, Boston, MA, USA) to discuss the findings from the dose response analysis of the INCREASE study.
The abstract entitled ‘DOSE RESPONSE ANALYSIS OF INHALED TREPROSTINIL IN PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE AND ITS EFFECTS ON CLINICAL WORSENING.’ was presented at CHEST 2021, 17-20 October 2021.
Questions
- Could you give us a brief overview of the occurrence of pulmonary hypertension (PH) in interstitial lung disease (ILD) and its prognostic significance? (0:21)
- What did the INCREASE study teach us about the efficacy and safety of inhaled treprostinil in patients with ILD and associated PH? (1:39)
- What were the aims and design of the current analysis? (2:39)
- What were the dose-response effects on clinical worsening and what are their clinical implications in terms of dose titration? (3:51)
- What were the limitations of this study? (6:07)
Disclosures: Aaron Waxman discloses being an investigator for United Therapeutics, Acceleron, Altavant, Gossamer, and ARIA-CV.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of CHEST 2021 (Virtual).
